New eye drug test aims to halt vision loss in older adults
NCT ID NCT07235527
Summary
This study is observing how well a biosimilar version of an existing eye injection works for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. It will follow 54 patients aged 45-90 who are already scheduled to receive this type of injection as part of their regular care. The main goal is to see if the treatment helps maintain or improve vision and reduces swelling in the back of the eye over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Prof. Dr. Cemil Taşcıoğlu City Hospital
RECRUITINGIstanbul, şişli, 34384, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.